{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T22:21:39Z","timestamp":1768342899757,"version":"3.49.0"},"reference-count":49,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["19-74-00151"],"award-info":[{"award-number":["19-74-00151"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>Schizophrenia is a serious mental disorder requiring lifelong treatment. While medications are available that are effective in treating some patients, individual treatment responses can vary, with some patients exhibiting resistance to one or multiple drugs. Currently, little is known about the causes of the difference in treatment response observed among individuals with schizophrenia, and satisfactory markers of poor response are not available for clinical practice. Here, we studied the changes in the levels of 322 blood plasma lipids between two time points assessed in 92 individuals diagnosed with schizophrenia during their inpatient treatment and their association with the extent of symptom improvement. We found 20 triglyceride species increased in individuals with the least improvement in Positive and Negative Syndrome Scale (PANSS) scores, but not in those with the largest reduction in PANSS scores. These triglyceride species were distinct from the rest of the triglyceride species present in blood plasma. They contained a relatively low number of carbons in their fatty acid residues and were relatively low in abundance compared to the principal triglyceride species of blood plasma.<\/jats:p>","DOI":"10.3390\/biom11050720","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T22:53:40Z","timestamp":1620773620000},"page":"720","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Shorter Chain Triglycerides Are Negatively Associated with Symptom Improvement in Schizophrenia"],"prefix":"10.3390","volume":"11","author":[{"given":"Anna","family":"Tkachev","sequence":"first","affiliation":[{"name":"V. Zelman Center for Neurobiology and Brain Restoration, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Stekolshchikova","sequence":"additional","affiliation":[{"name":"V. Zelman Center for Neurobiology and Brain Restoration, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nickolay","family":"Anikanov","sequence":"additional","affiliation":[{"name":"V. Zelman Center for Neurobiology and Brain Restoration, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5390-6007","authenticated-orcid":false,"given":"Svetlana","family":"Zozulya","sequence":"additional","affiliation":[{"name":"Mental Health Research Center, 115522 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aleksandra","family":"Barkhatova","sequence":"additional","affiliation":[{"name":"Mental Health Research Center, 115522 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatiana","family":"Klyushnik","sequence":"additional","affiliation":[{"name":"Mental Health Research Center, 115522 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-1717","authenticated-orcid":false,"given":"Daria","family":"Petrova","sequence":"additional","affiliation":[{"name":"V. Zelman Center for Neurobiology and Brain Restoration, Skolkovo Institute of Science and Technology, 121205 Moscow, Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"McCutcheon, R.A., Pillinger, T., Mizuno, Y., Montgomery, A., Pandian, H., Vano, L., Marques, T.R., and Howes, O.D. (2019). The efficacy and heterogeneity of antipsychotic response in schizophrenia: A meta-analysis. Mol. Psychiatry, 1\u201311.","DOI":"10.1093\/schbul\/sbaa029.605"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41537-019-0090-z","article-title":"The neurobiology of treatment-resistant schizophrenia: Paths to antipsychotic resistance and a roadmap for future research","volume":"6","author":"Potkin","year":"2020","journal-title":"NPJ Schizophr."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1093\/schbul\/sbv002","article-title":"The promise of biological markers for treatment response in first-episode psychosis: A systematic review","volume":"41","author":"Fond","year":"2015","journal-title":"Schizophr. Bull."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nrd1776","article-title":"The emerging field of lipidomics","volume":"4","author":"Wenk","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"e1466","DOI":"10.1002\/wsbm.1466","article-title":"Lipidomics: Current state of the art in a fast moving field","volume":"12","author":"Ekroos","year":"2020","journal-title":"Wiley Interdiscip. Rev. Syst. Biol. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/nrn2233","article-title":"A neuroscientist\u2019s guide to lipidomics","volume":"8","author":"Piomelli","year":"2007","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neuron.2016.02.033","article-title":"Membrane Lipids in Presynaptic Function and Disease","volume":"90","author":"Lauwers","year":"2016","journal-title":"Neuron"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41398-018-0353-x","article-title":"Characterizing acyl-carnitine biosignatures for schizophrenia: A longitudinal pre- and post-treatment study","volume":"9","author":"Cao","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.schres.2014.11.032","article-title":"Dysfunctional plasmalogen dynamics in the plasma and platelets of patients with schizophrenia","volume":"161","author":"Wood","year":"2015","journal-title":"Schizophr. Res."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"3558","DOI":"10.1021\/acs.jproteome.7b00279","article-title":"Profiling of acylcarnitines in first episode psychosis before and after antipsychotic treatment","volume":"1","author":"Kriisa","year":"2017","journal-title":"J. Proteome Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00406-018-0971-6","article-title":"Profiling of lipidomics before and after antipsychotic treatment in first-episode psychosis","volume":"270","author":"Leppik","year":"2020","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11306-018-1375-3","article-title":"Unbiased lipidomic profiling reveals metabolomic changes during the onset and antipsychotics treatment of schizophrenia disease","volume":"14","author":"Yan","year":"2018","journal-title":"Metabolomics"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.psychres.2018.12.008","article-title":"Metabolic profiling identifies phospholipids as potential serum biomarkers for schizophrenia","volume":"272","author":"Wang","year":"2019","journal-title":"Psychiatry Res."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Wang, D., Sun, X., Maziade, M., Mao, W., Zhang, C., Wang, J., and Cao, B. (2020). Characterising phospholipids and free fatty acids in patients with schizophrenia: A case-control study. World J. Biol. Psychiatry, 1\u201314.","DOI":"10.1080\/15622975.2020.1769188"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1080\/15622975.2019.1615639","article-title":"Metabolic profiling for water-soluble metabolites in patients with schizophrenia and healthy controls in a Chinese population: A case-control study","volume":"21","author":"Cao","year":"2020","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1038\/tp.2012.76","article-title":"Schizophrenia shows a unique metabolomics signature in plasma","volume":"2","author":"He","year":"2012","journal-title":"Transl. Psychiatry"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.metabol.2019.04.002","article-title":"Targeted lipidomics reveal derangement of ceramides in major depression and bipolar disorder","volume":"95","author":"Hackel","year":"2019","journal-title":"Metabolis"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1176\/jnp.23.2.jnp215","article-title":"Elevated plasma ceramides in depression","volume":"23","author":"Rao","year":"2011","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"6497","DOI":"10.1007\/s00216-016-9768-5","article-title":"Plasma lipidomics reveals potential lipid markers of major depressive disorder","volume":"408","author":"Liu","year":"2016","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1021\/acs.jproteome.5b00144","article-title":"Discovery and validation of plasma biomarkers for major depressive disorder classification based on liquid chromatography-mass spectrometry","volume":"14","author":"Liu","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jpsychires.2012.11.001","article-title":"Plasma phosphatidylcholine and sphingomyelin concentrations are associated with depression and anxiety symptoms in a Dutch family-based lipidomics study","volume":"47","author":"Demirkan","year":"2013","journal-title":"J. Psychiatr. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"5765","DOI":"10.1007\/s00216-019-01956-2","article-title":"Quantitative monitoring of a panel of stress-induced biomarkers in human plasma by liquid chromatography-tandem mass spectrometry: An application in a comparative study between depressive patients and healthy subjects","volume":"411","author":"Cai","year":"2019","journal-title":"Anal. Bioanal. Chem."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.psychres.2018.04.029","article-title":"Serum lipidomic analysis for the discovery of biomarkers for major depressive disorder in drug-free patients","volume":"265","author":"Kim","year":"2018","journal-title":"Psychiatry Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.psychres.2012.02.019","article-title":"Impaired plasmalogens in patients with schizophrenia","volume":"198","author":"McEvoy","year":"2012","journal-title":"Psychiatry Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/pcn.12779","article-title":"Serum metabolic profiling using small molecular water-soluble metabolites in individuals with schizophrenia: A longitudinal study using a pre\u2013post-treatment design","volume":"73","author":"Cao","year":"2019","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1080\/15622975.2016.1178803","article-title":"Comparison of serum carnitine levels and clinical correlates between outpatients and acutely hospitalised individuals with bipolar disorder and schizophrenia: A cross-sectional study","volume":"17","author":"Cuturic","year":"2016","journal-title":"World J. Biol. Psychiatry"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.eurpsy.2017.02.479","article-title":"The lipidome in major depressive disorder: Shared genetic influence for ether-phosphatidylcholines, a plasma-based phenotype related to inflammation, and disease risk","volume":"43","author":"Knowles","year":"2017","journal-title":"Eur. Psychiatry"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jad.2017.02.008","article-title":"Ceramides and depression: A systematic review","volume":"213","author":"Dinoff","year":"2017","journal-title":"J. Affect. Disord."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wong, M.W.K., Braidy, N., Pickford, R., Vafaee, F., Crawford, J., Muenchhoff, J., Schofield, P., Attia, J., Brodaty, H., and Sachdev, P. (2019). Plasma lipidome variation during the second half of the human lifespan is associated with age and sex but minimally with BMI. PLoS ONE, 14.","DOI":"10.1371\/journal.pone.0214141"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Beyene, H.B., Olshansky, G., Smith, A.A.T., Giles, C., Huynh, K., Cinel, M., Mellett, N.A., Cadby, G., Hung, J., and Hui, J. (2020). High-coverage plasma lipidomics reveals novel sex-specific lipidomic fingerprints of age and BMI: Evidence from two large population cohort studies. PLoS Biol., 18.","DOI":"10.1371\/journal.pbio.3001049"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12888-018-1950-1","article-title":"Early predictors of poor treatment response in patients with schizophrenia treated with atypical antipsychotics","volume":"18","author":"Chen","year":"2018","journal-title":"BMC Psychiatry"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"109945","DOI":"10.1016\/j.pnpbp.2020.109945","article-title":"Changes in the blood plasma lipidome associated with effective or poor response to atypical antipsychotic treatments in schizophrenia patients","volume":"101","author":"Alexandrino","year":"2020","journal-title":"Prog. Neuro Psychopharmacol. Biol. Psychiatry"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e906","DOI":"10.1038\/tp.2016.142","article-title":"Membrane lipidomics in schizophrenia patients: A correlational study with clinical and cognitive manifestations","volume":"6","author":"Tessier","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1021\/ac051437y","article-title":"XCMS: Processing mass spectrometry data for metabolite profiling using nonlinear peak alignment, matching, and identification","volume":"78","author":"Smith","year":"2006","journal-title":"Anal. Chem."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1194\/jlr.S087163","article-title":"MS-based lipidomics of human blood plasma: A community-initiated position paper to develop accepted guidelines","volume":"59","author":"Burla","year":"2018","journal-title":"J. Lipid Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1176\/ajp.152.5.698","article-title":"Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients","volume":"152","author":"Szymanski","year":"1995","journal-title":"Am. J. Psychiatry"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.4088\/JCP.11m07422","article-title":"Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients","volume":"73","author":"Zhang","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2174\/1570159X17666190228113348","article-title":"Association between Serum Lipids and Antipsychotic Response in Schizophrenia","volume":"17","author":"Kim","year":"2019","journal-title":"Curr. Neuropharmacol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e951","DOI":"10.1038\/tp.2016.222","article-title":"Serum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis","volume":"6","author":"Suvitaival","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1172\/JCI44442","article-title":"Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans","volume":"121","author":"Rhee","year":"2011","journal-title":"J. Clin. Investig."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1007\/s00125-013-2981-2","article-title":"Prediction of non-alcoholic fatty-liver disease and liver fat content by serum molecular lipids","volume":"56","author":"Kotronen","year":"2013","journal-title":"Diabetologia"},{"key":"ref_43","first-page":"1","article-title":"Effects of olanzapine treatment on lipid profiles in patients with schizophrenia: A systematic review and meta-analysis","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.schres.2004.01.014","article-title":"The effects of antipsychotic therapy on serum lipids: A comprehensive review","volume":"70","author":"Meyer","year":"2004","journal-title":"Schizophr. Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1093\/schbul\/sbr148","article-title":"Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis","volume":"39","author":"Mitchell","year":"2013","journal-title":"Schizophr. Bull."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"63","DOI":"10.31887\/DCNS.2018.20.1\/bpenninx","article-title":"Metabolic syndrome in psychiatric patients: Overview, mechanisms, and implications","volume":"20","author":"Penninx","year":"2018","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_47","first-page":"49","article-title":"Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology ESC","volume":"2","author":"Hert","year":"2009","journal-title":"Eur. Psychiatry"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"47","DOI":"10.31887\/DCNS.2018.20.1\/nsartorius","article-title":"Depression and diabetes","volume":"20","author":"Sartorius","year":"2018","journal-title":"Dialogues Clin. Neurosci."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1093\/schbul\/sbw058","article-title":"Pharmacogenetic Associations of Antipsychotic Drug-Related Weight Gain: A Systematic Review and Meta-analysis","volume":"42","author":"Zhang","year":"2016","journal-title":"Schizophr. Bull."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/5\/720\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:59:25Z","timestamp":1760162365000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/11\/5\/720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":49,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"alternative-id":["biom11050720"],"URL":"https:\/\/doi.org\/10.3390\/biom11050720","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]}}}